In Vivo Gene Editing Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to bring the same structured evidence into your own AI workflow.
Data snapshot: 16 July 2026. This landscape is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
In-vivo editing has crossed from early safety studies into pivotal testing, but the competitive moat will depend on delivery, durability, off-target monitoring, and whether one-time benefit clearly exceeds chronic therapy.
How this report was built with PatSnap MCP
The workflow first used the Clinical Trials MCP to search the topic and then called clinical_trial_fetch for design details: phase, status, enrollment, sponsor, geography, primary endpoint and expected timing. It separately used clinical_trial_result_fetch to inspect indexed readouts. The Drug & Asset MCP drug_fetch call added target and global development status, while Company & Deal Intelligence organization_fetch added sponsor context. This sequence keeps trial claims traceable and prevents asset-level assumptions from being inferred from a company name alone.
Trial landscape table
| Trial | Asset / mechanism | Phase / status | Sponsor | Geography | Primary endpoint | Readout |
|---|---|---|---|---|---|---|
| NCT06634420 | Lonvoguran / NTLA-2002 (KLKB1) | Phase 3; active | Intellia Therapeutics | 9 countries | Investigator-confirmed HAE attack rate, weeks 5–28 | Primary completed Feb 2026 |
| NCT06164730 | VERVE-102 (PCSK9) | Phase 1; recruiting | Verve Therapeutics | 6 countries | TEAEs and SAEs through day 365 | Primary completion Aug 2026 |
| NCT05398029 | VERVE-101 (PCSK9) | Phase 1; completed | Verve Therapeutics | New Zealand, UK | TEAEs, SAEs and AESIs | Primary completed Feb 2025 |
| NCT05120830 | Lonvoguran / NTLA-2002 | Phase 1/2; active | Intellia Therapeutics | 6 countries | Safety plus monthly HAE attacks | Primary completed Apr 2024 |
The table is intentionally decision-oriented: endpoint choice, geographic reach and readout timing are displayed beside phase and sponsor. A large Phase 3 program can still have a long evidence gap, while a small Phase 2 study may answer a strategically important biomarker or tolerability question sooner.
What the indexed results say
- The pivotal HAELO design uses investigator-confirmed attack frequency, connecting a molecular edit to an outcome that matters directly to patients.
- Cardiovascular base-editing programs remain safety-led in Phase 1, with one-year adverse-event windows before outcomes-scale studies can be justified.
- The contrast between KLKB1 and PCSK9 programs shows how liver delivery is becoming a platform, while indication risk and acceptable safety thresholds remain disease-specific.
Result records should be interpreted in context. Cross-trial comparisons can be distorted by population, baseline risk, estimand, dose, follow-up and analysis set. The useful signal is not a simplistic ranking; it is how each result changes the next development question.
Build your own living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling multiple databases.
Asset and sponsor context
Drug & Asset records show lonvoguran targeting KLKB1 at NDA/BLA status, while VERVE-101 and VERVE-102 target PCSK9 in Phase 1. Organization data identify Intellia (NTLA) and Verve (VERV) as the principal sponsors in this focused sample.
Where the white space is
- Cross-platform standards for off-target, immunogenicity and germline-exposure monitoring.
- Evidence comparing one-time editing with effective chronic prophylaxis or lipid lowering.
- Delivery beyond the liver and redosing strategies when the first edit is incomplete.
- Long-term registries linking edit durability to hard clinical outcomes.
Strategic implications
For sponsors, the strongest differentiation opportunity is usually not “another asset in the same class.” It is a trial package that resolves a known decision gap: an active comparator, a better-defined responder population, a safer delivery model, a hard outcome, or a credible plan for sequencing. For business-development teams, the same landscape can identify assets whose mechanism is crowded but whose evidence architecture is differentiated. For investors, endpoint maturity and operational feasibility deserve as much attention as nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, and sponsor ownership. Re-run the same MCP queries on a schedule and compare deltas rather than rebuilding the landscape from scratch. Pay special attention when an endpoint moves from a surrogate to a clinical outcome, when a single-country program becomes multinational, or when an emerging sponsor adds a large pharmaceutical collaborator.
Bottom line
In Vivo Gene Editing is a fast-moving clinical field with meaningful competition and equally meaningful evidence gaps. A useful landscape must connect design, results, mechanism and sponsor—not list trials in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for research, monitoring and SEO-ready clinical reports.
